Technology — AptaSure™ | Invenio Medical

01 // The building block

What is an aptamer?

Picture a molecular key cut to fit exactly one lock. An aptamer is a short, single strand of synthetic DNA or RNA that folds into a precise three-dimensional shape — and that shape grips one chosen target, such as a bacterial protein, with the pinpoint specificity of an antibody.

Each aptamer is discovered through directed evolution: vast libraries of random sequences are screened round after round, keeping only the strands that bind the target best. The winner is then manufactured as a defined chemical — no animals and no cell lines, so there's far less of the biological variability that can complicate antibodies.

Why that matters for a test meant to work anywhere:

Rugged. Synthetic strands tolerate heat and long storage better than many proteins — well suited to use outside the lab.
Reproducible. Every lot is chemically defined, so behavior doesn't drift from batch to batch.
Scalable & affordable. Synthesized by the gram rather than grown — built for high volume.
Engineerable. Can be tuned to favor the exact target site that yields a clean, unambiguous signal.

02 // How AptaSure works

A dual-aptamer lateral-flow assay for MRSA.

AptaSure™ MRSA detects pbp2a — the protein that makes Staphylococcus aureus methicillin-resistant — using a cognate pair of aptamers and gold-nanoparticle signal, read by eye like a rapid test.

AptaSure MRSA point-of-care test device — The AptaSure™ MRSA device — swab, snap the pre-measured buffer, and read the colorimetric C/T result in minutes. Still from the product preview video; swap for a final asset when ready.

STEP // 01

Capture

A gold-nanoparticle–labeled aptamer binds the MRSA marker protein pbp2a in the sample.

STEP // 02

Confirm

A second, cognate aptamer binds pbp2a at a different site — a two-point lock that drives specificity and reduces false reads.

STEP // 03

Read

The complex concentrates at the test line, producing a visible result in minutes — no instrument required.

03 // The first target

Why MRSA, and why speed.

Methicillin-resistant S. aureus is one of the most consequential healthcare-associated infections. Conventional identification relies on culture that can take 1–3 days — time in which patients are treated empirically.

A rapid, point-of-care answer is designed to support earlier, more targeted decisions — the kind of difference that matters for both patient outcomes and cost of care.

~10 min

to a visual result, vs. days for culture

0°

refrigeration required — shelf-stable, single-use

04 // How it compares

Built to fit where current methods don't.

	Lab culture	AptaSure™ (design goals)
Time to result	1–3 days	~10 minutes
Where it runs	Central laboratory	Point of care
Instrument	Lab equipment	None — visual read
Cold chain	Often required	Not required
Binding chemistry	—	Dual aptamer to pbp2a

Comparison reflects design goals for an investigational device in development.

05 // Development & validation

Advancing through the FDA 510(k) pathway.

AptaSure™ MRSA is being developed with research and clinical partners, with assay optimization and specificity testing conducted during development. The 510(k) submission package is complete and has been refined across multiple validation runs with additional testing as required; formal submission to the FDA is pending payment of the application fee.

Learn more

Want the technical and investor details?

We share development data and the regulatory roadmap with qualified partners and investors under NDA.

Investor portal

Molecular precision, point-of-care simplicity.